X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA FDC LTD. AJANTA PHARMA/
FDC LTD.
 
P/E (TTM) x 20.1 18.1 111.2% View Chart
P/BV x 4.7 4.1 114.6% View Chart
Dividend Yield % 0.0 1.2 -  

Financials

 AJANTA PHARMA   FDC LTD.
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
FDC LTD.
Mar-14
AJANTA PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs1,818144 1,266.9%   
Low Rs1,10679 1,400.0%   
Sales per share (Unadj.) Rs239.547.6 503.5%  
Earnings per share (Unadj.) Rs52.87.6 693.8%  
Cash flow per share (Unadj.) Rs59.59.0 660.4%  
Dividends per share (Unadj.) Rs02.25 0.0%  
Dividend yield (eoy) %02.0 0.0%  
Book value per share (Unadj.) Rs230.047.5 483.8%  
Shares outstanding (eoy) m88.77177.83 49.9%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x6.12.3 261.0%   
Avg P/E ratio x27.714.6 189.4%  
P/CF ratio (eoy) x24.612.3 199.0%  
Price / Book Value ratio x6.42.3 271.6%  
Dividend payout %029.6 0.0%   
Avg Mkt Cap Rs m129,78219,784 656.0%   
No. of employees `0006.8NA-   
Total wages/salary Rs m3,7651,221 308.5%   
Avg. sales/employee Rs Th3,128.4NM-  
Avg. wages/employee Rs Th554.0NM-  
Avg. net profit/employee Rs Th689.7NM-  
INCOME DATA
Net Sales Rs m21,2588,459 251.3%  
Other income Rs m242394 61.4%   
Total revenues Rs m21,4998,852 242.9%   
Gross profit Rs m6,5842,070 318.0%  
Depreciation Rs m596249 239.2%   
Interest Rs m431 13.2%   
Profit before tax Rs m6,2262,184 285.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,539606 254.2%   
Profit after tax Rs m4,6861,353 346.3%  
Gross profit margin %31.024.5 126.5%  
Effective tax rate %24.727.7 89.1%   
Net profit margin %22.016.0 137.8%  
BALANCE SHEET DATA
Current assets Rs m12,2364,355 280.9%   
Current liabilities Rs m3,4611,792 193.1%   
Net working cap to sales %41.330.3 136.2%  
Current ratio x3.52.4 145.5%  
Inventory Days Days6044 135.5%  
Debtors Days Days8425 342.5%  
Net fixed assets Rs m11,1403,025 368.3%   
Share capital Rs m177179 99.0%   
"Free" reserves Rs m20,2378,243 245.5%   
Net worth Rs m20,4148,453 241.5%   
Long term debt Rs m1011 94.4%   
Total assets Rs m24,48610,557 231.9%  
Interest coverage x1,519.471.4 2,127.6%   
Debt to equity ratio x00 39.1%  
Sales to assets ratio x0.90.8 108.4%   
Return on assets %19.213.1 146.1%  
Return on equity %23.016.0 143.4%  
Return on capital %30.523.5 129.7%  
Exports to sales %013.3 0.0%   
Imports to sales %03.3 0.0%   
Exports (fob) Rs mNA1,126 0.0%   
Imports (cif) Rs mNA283 0.0%   
Fx inflow Rs m11,6671,146 1,018.0%   
Fx outflow Rs m1,616355 454.7%   
Net fx Rs m10,052791 1,271.1%   
CASH FLOW
From Operations Rs m2,8541,485 192.2%  
From Investments Rs m-2,604-620 420.4%  
From Financial Activity Rs m-2-753 0.3%  
Net Cashflow Rs m248113 219.9%  

Share Holding

Indian Promoters % 73.8 68.9 107.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 4.7 33.0%  
FIIs % 7.6 7.5 101.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 19.0 89.5%  
Shareholders   20,968 23,730 88.4%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ORCHID PHARMA LTD  CIPLA  ABBOTT INDIA  ALEMBIC LTD  WYETH LTD  

Compare AJANTA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

FDC LTD. Announces Quarterly Results (1QFY19); Net Profit Up 74.5% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, FDC LTD. has posted a net profit of Rs 511 m (up 74.5% YoY). Sales on the other hand came in at Rs 3 bn (up 16.7% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Nov 15, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS